Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil pre-injection to reduce etomidate-induced muscle spasm and effects on intragastric pressure
ChiCTR2400084414Phase 4Recruiting
- Sponsor
- University of Chinese Academy of Sciences Shenzhen Hospital
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sufentanil and etomidate in Muscle spasm and None (2 arms), sponsored by University of Chinese Academy of Sciences Shenzhen Hospital. Primary endpoints: Etomidate-induced muscle cramp (myoclonus) and Intragastric pressure. Started May 2024; status: recruiting.
02
Drugs
sufentaniletomidate
03
Conditions
Muscle spasm
Beyond the preview
Go deeper on ChiCTR2400084414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084414.